{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-279380","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2023-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.244901+00:00","generated_at":"2026-06-08T00:27:47.130858+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MAIA Biotechnology raises $4M in registered direct offering; discloses NYSE American equity non-compliance","bullets":["Sold 2,424,243 shares at $1.65/sh; warrants exercisable at $1.86/sh for 5.5 years.","Gross proceeds ~$4M; net to company ~$3.47M; closing expected Nov 17, 2023.","NYSE American orally advised MAIA it fails stockholders' equity standard ($2.7M vs $4M minimum).","Company believes after offering stockholders' equity will exceed $4M, addressing non-compliance.","H.C. Wainwright acted as exclusive placement agent; lock-up agreements for 60 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-279380","json":"https://secwatch.observer/filing/0001193125-23-279380.json","markdown":"https://secwatch.observer/filing/0001193125-23-279380.md","text":"https://secwatch.observer/filing/0001193125-23-279380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000119312523279380/0001193125-23-279380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000119312523279380/d614732d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T00:27:47.130858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b95516ebac4ec523695d20b7ce5c18998b824d55","claim":"MAIA Biotechnology, Inc. entered into Securities Purchase Agreement with three institutional accredited investors valued at gross proceeds of approximately $4.0 million (effective 2023-11-15).","evidence_excerpt":"On November 15, 2023, MAIA Biotechnology, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with three institutional accredited investors (the “Investors”) pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of NYSE American (the “Registered Offering”), 2,424,243 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), at a price per Share of $1.65.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1878313/000119312523279380/0001193125-23-279380-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"three institutional accredited investors"},{"label":"Value","value":"gross proceeds of approximately $4.0 million"},{"label":"Effective","value":"2023-11-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}